CureHepC_PreventHIV.jpeg

We Cure Hep C & Prevent HIV: Two Bold Commitments — One Clinic, One Mission

We live by a simple but powerful slogan: “We Cure Hep C & Prevent HIV.” This isn’t just marketing—it’s a statement of what we do every day. Through inclusive, judgment-free, community-grounded care, we aim to end one epidemic and stop another right at its source.

Why the dual focus?

  • Hepatitis C (Hep C) is curable. Thanks to highly effective direct-acting antivirals (DAAs), a sustained virologic response (SVR) is achieved in the vast majority of people who complete treatment.
  • HIV, while not yet fully curable, is highly preventable. Through prevention tools like pre-exposure prophylaxis (PrEP) and regular testing, we reduce new transmissions and empower people with status knowledge.

Together, these efforts reflect a continuum of care: from screening and treatment to prevention and education—and all wrapped in affirming, accessible care for LGBTQIA+ and underserved communities.

How We Cure Hep C

  • We integrate low-barrier testing, outreach, and treatment protocols in clinics, mobile units, and community settings. Research shows that community-based, point-of-diagnosis treatment models increase access and outcomes.
  • We follow simplified algorithms so more patients—including people who use drugs or who have not been in care—can be treated.
  • Our team supports patients through every step: testing, baseline evaluation (including liver health), prescribing DAAs, follow-up labs, and linkage to supportive services—because curing Hep C is about more than pills; it’s about removing barriers.

How We Prevent HIV

  • Testing: We offer routine HIV screening because early diagnosis = early care.
  • PrEP: We offer daily oral PrEP and keep up-to-date on new modalities, because when taken as prescribed, PrEP reduces sexual transmission of HIV by about 99 %.
  • Holistic care: We don’t treat HIV prevention in a bubble. We address sexual wellness, substance use, mental health, housing, stigma—because social drivers of health matter.
  • Education & navigation: Many people still don’t know about PrEP or how to access it. We walk with you: questions, insurance support, medication adherence, and peer support.

Why These Two Together?

Linking Hep C and HIV isn’t coincidental. They often share routes of transmission or social vulnerabilities, especially in communities facing intersecting stigma and barriers to care. By doing both, we:

  • Maximize impact in sexual-health and harm-reduction services
  • Reach broader populations (e.g., people who inject drugs, LGBTQIA+ folks, people experiencing homelessness)
  • Build trust and continuity in care, because your health isn’t siloed

What This Means for You

  • If you’ve never been tested for Hep C (or HIV), we’ve got you. 
  • If you’ve been told you have Hep C in the past and didn’t follow up, recent treatments are simpler, faster, and more effective than ever.
  • If you’re HIV-negative and sexually active or use injection drugs, you might benefit from PrEP. Ask us and we’ll walk you through what’s right for you.
  • If you’re living with HIV or know someone who is—our goal is your holistic health: viral suppression, prevention of other infections, and full wellness.

Our Promise

At Central Outreach, “We Cure Hep C & Prevent HIV” is more than a slogan—it’s a promise. A promise to show up, dismantle barriers, fight stigma, and stand beside our communities. Because every body deserves care, and every story deserves a healing arc.

Sources

  1. Ramers CB, et al. “Simplified and integrated hepatitis C virus testing and treatment algorithm in urban outreach settings.” Open Forum Infectious Diseases. 2025. OUP Academic+1
  2. Corcorran MA. “Simplified HCV treatment for all genotypes: a core-concept review.” Hepatitis C Online. Hepatitis C Online
  3. “Pre-exposure prophylaxis (PrEP): Why take PrEP?” HIVinfo NIH. HIV.gov
  4. “Clinical Guidance for PrEP.” Centers for Disease Control and Prevention (CDC). CDC
  5. Kelley K. “Review of treatment of hepatitis C among persons who use drugs: 2025 update.” Springer. link.springer.com